Novotech Expands Services to China
Novotech, Australia?s largest clinical CRO with offices throughout Asia, announced today the expansion of services to China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia.
Novotech, an Australian CRO with offices throughout Asia,
China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia. Novotech Asia COO, Dr. John Moller said China is now the largest clinical trial destination in Asia, and the 5th largest in the world.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMGSeptember 15th 2025
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
